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Dynamic laryngoscopy during noninvasive (NIV) respiratory therapy is feasible and 
may facilitate optimal and individualized treatment in patients with chronic respira-
tory failure, also in children.
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1 |  INTRODUCTION
Following Spinraza©, children with Spinal Muscular Atrophy 
(SMA) face a possibility of better health, most particularly 
those with SMA type I, who previously died early. Effective 
respiratory aids are crucial to prevent and treat respiratory 
complications and maintain quality of life. We shed light on 
a challenge in the respiratory management in children with 
SMA type I.
2 |  CASE REPORT
An infant child displayed profound muscular hypotonia and 
poor head control, progressing from 6 weeks of age. SMA 
type I was diagnosed at 5  months of age, genetic tests re-
vealed lack of the Survival Motor Neuron (SMN) 1 gene, and 
two SMN2 gene copies. CHOP INTEND (The Children's 
Hospital of Philadelphia Infant Test of Neuromuscular disor-
ders motor function score) was 35/64, the child was cognitive 
alert, smiled, had weak cough, weak voice, bell- shaped tho-
rax, normal SpO2, and transcutaneous CO2 during sleep at the 
first visit to the pulmonologist. The child had the first dose 
of Spinraza 3 days after genetic diagnosis. Immunizations for 
Respiratory Syncytial virus and Influenza were given. We 
planned equipment for respiratory support, and parents and 
health personnel received organized training. At 6 months, 
following a viral lower respiratory infection during which the 
child was critically ill, the child started using bilevel posi-
tive airway pressure (BIPAP) during sleep and as intermittent 
high- span treatment, as well as mechanical insufflation- 
exsufflation (MI- E) device daily, all in the family home.
At 6, 7, and 9 months, the child was admitted acutely 
for severe illness during viral pneumonias, needing 
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prolonged intensive care with noninvasive ventilation 
(NIV). The child started using intermittent negative pres-
sure ventilation and intrapulmonary percussive ventila-
tion. Pseudomonas aeruginosa grew in tracheal aspirates, 
treatment commenced accordingly, with intravenous and 
inhaled antibiotics as well as inhaled hypertonic saline 
2.8% daily, due to excessive secretions. This treatment led 
to successful eradication.
The child breastfed initially, but swallowing difficulties 
increased and weight gain flattened. The child had a nasogas-
tric tube at 7 months of age, and a percutaneous gastrostomy 
at 9 months, by when the child tolerated only minimal oral 
liquids or solids without needing support.
At 11  months, Chop- Intend score was 45/64, respira-
tory status was unchanged, the child used BIPAP during all 
sleep and more during airway infections, which were still 
frequent, and they had to bring the MI- E device and suc-
tion aids wherever they traveled outside their home. The 
parents now reported periodic problems with the MI- E de-
vice, as difficulties inflating the child's chest and evacuating 
secretions.
At 12 months of age, we performed dynamic transnasal fi-
beroptic laryngoscopy (TFL) during ongoing MI- E treatment, 
after nasal decongestion spray, and with Xylocaine lubricant 
gel on the laryngoscope.1 A Toddler Facemask (Respironics 
Cough Assist Accessories), was customized with an extra 
opening for the laryngoscope. The child was awake and sit-
ting supported in the mother's lap. A direct laryngeal image 
revealed increased amounts of secretions in oropharynx 
and supraglottis, indicating ongoing aspiration (Figure  1). 
Insufflation pressures of +35  cm H2O provoked adduction 
of supraglottic structures1 (Figure  2A). By simultaneously 
reducing the inspiratory flow and the insufflation pressure to 
+25 cm H2O, the child responded with laryngeal abduction 
(Figure 2B). The child tolerated the procedure well, without 
objecting or crying. Air- flow patterns registered by the MI- E 
device were studied afterwards, revealing altered insufflation 
flow geometry with the initial settings, improving after mod-
ifying the flow and pressure as described (Figure 2).
3 |  DISCUSSION
Spinal muscular atrophy is an autosomal recessive disease 
caused by a homozygous deletion in the Survival Motor Neuron 
(SMN) 1 gene on chromosome 5. With loss of SMN protein, 
progressive loss of spinal lower motor neurons commences in 
the anterior horn of the spinal cord, causing advanced atrophy 
of skeletal muscle. SMA clinically subtypes into four, type I 
being most common and most severe. While appearing normal 
at birth, symptoms present before 6 months of age, with the 
child being progressively hypotonic, losing most strength and 
movement in the limbs, with poor head control, weak swallow-
ing, frequent aspiration and failure to thrive, but normal cog-
nition.2 Due to marked respiratory muscle weakness, infants 
rapidly progress to respiratory failure, previously most died 
prior to 2 years of age.
The oligonucleotide Spinraza© (Nusinersen) is an intra-
thecal drug acting as a splicing modifier in the SMN2 protein 
production, enhancing the production of functioning SMN2 
protein. Due to promising results with improvement in motor 
milestones as well as event- free survival (time to death or 
use of assisted ventilation), Spinraza was rapidly introduced, 
following limited trials.3 This dramatically changed the 
treatment paradigm for SMA I. Affected children may now 
survive, some exhibit head control and sit, stand, or walk in-
dependently, however, many still have poor motor, feeding, 
and respiratory function, and dependency on technical respi-
ratory aids.4 Long- term treatment effects remain unknown.5 
This raises important ethical concerns. The daily treatment in 
these children needs to be efficient, well- tolerated, and im-
proving life quality.
Our SMA I patient had a clear motor effect of Spinraza, 
although less effect on respiration and feeding. Dynamic 
laryngoscopy during ongoing MI- E revealed signs of as-
piration, as well as laryngeal closure in response to high 
inspirational pressures, indicating bulbar affection— in line 
with clinical observations— and similar to what we previ-
ously observed in adult patients with Amyotrophic Lateral 
Sclerosis (ALS).1
F I G U R E  1  Depicts the view through 
the laryngoscope A, of the nasopharynx and 
B, of the supraglottis and glottic area
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The application of TFL during NIV treatment enabled 
us to adjust MI- E settings directly, by titrating insufflation 
pressures and flow to the most optimal levels of laryngeal 
opening, partly alluded to in a previous model.6 The pro-
cedure led to immediate changes in treatment. When set-
ting up technical respiratory aids, individual adaptations 
are compulsory. If the patient shows evidence of poor toler-
ance or inability to respond as wished, adjustments should 
commence accordingly. If problems appear and persist, dy-
namic TFL could be a valuable and well- tolerated tool, by 
providing direct views of the oropharynx and larynx, and 
responses to ongoing treatment. Our patient tolerated the 
procedure excellent, perhaps because the child was familiar 
with frequent suctioning of the upper airways through the 
nose.
4 |  CONCLUSION
We propose that dynamic laryngoscopy during noninva-
sive respiratory therapy may facilitate optimal and individ-
ualized NIV treatment in patients with chronic respiratory 
failure, also in pediatric patients. It is a feasible aid that 
might be used to directly adjust complex respiratory 
treatment.
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